{'fraction_non_alphanumeric': 0.029469548133595286, 'fraction_numerical': 0.011787819253438114, 'mean_word_length': 5.574193548387097, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Surgery for gastrointestinal stromal tumours in Australia and New Zealand: results from a bi‐national audit

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract and account for 1–2% of all gastrointestinal malignancies. In terms of metastatic potential, GISTs encompass a continuum of small, mitotically inactive tumours up to larger, active tumours. Surgical resection is considered standard of care for localized GISTs. Population-based studies have been published from 19 countries, and they report annual incidence rates between 4.3 and 22 per million. There is no published data from Australia, and one recent review from New Zealand. Given the relative rarity of GISTs, the bi-national Australia & New Zealand Gastric & Oesophageal Surgery Association (ANZGOSA) Audit, commenced in 2010, is ideally suited to determine disease burden, tumour characteristics and treatment patterns of GISTs, including incidence if possible, in Australia and New Zealand.